ClinicaliQ Trial Snapshot
- A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia — Active Not Recruiting • Phase III • NCT04812925.
- Efgartigimod injections under the skin improved platelet counts in adults with immune thrombocytopenia, showing good safety.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia Conditions: Primary Immune Thrombocytopenia Interventions: efgartigimod PH20 SC Lead Sponsor: argenx Planned Enrollment: 173 participants